Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with a new stable
Fusion Antibodies (AIM:FAB) OptiMAL R&D Update
OptiMAL® R&D Update
Zak Mir talks to Adrian Kinkaid, CEO (AIM:FAB) Fusion Antibodies
Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023